DM
CYTK icon

Deerfield Management’s Cytokinetics CYTK Stock Holding History

Deerfield Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,884
Closed -$680K – 199
2024
Q3 		$680K Buy
12,884
+8,518
+195% +$475K 0.01% 234
2024
Q2 		$237K Sell
4,366
-1,398
-24% -$84.4K ﹤0.01% 382
2024
Q1 		$404K Buy
5,764
+2,600
+82% +$201K 0.01% 186
2023
Q4 		$264K Buy
+3,164
New +$115K ﹤0.01% 138
2022
Q4 		– Sell
-813,112
Closed -$39.4M – 108
2022
Q3 		$39.4M Sell
813,112
-347,203
-30% -$16.7M 0.78% 42
2022
Q2 		$45.6M Buy
1,160,315
+207,612
+22% +$8.36M 0.94% 39
2022
Q1 		$35.1M Buy
952,703
+143,703
+18% +$5.11M 0.78% 39
2021
Q4 		$36.9M Sell
809,000
-727,758
-47% -$28.1M 0.77% 39
2021
Q3 		$54.9M Buy
1,536,758
+298,675
+24% +$8.79M 1.07% 26
2021
Q2 		$24.5M Sell
1,238,083
-1,322,917
-52% -$31.1M 0.44% 75
2021
Q1 		$59.6M Buy
2,561,000
+100,000
+4% +$2.14M 1.25% 21
2020
Q4 		$51.1M Buy
+2,461,000
New +$45M 1.01% 29
2013
Q3 		– Sell
-1,779,622
Closed -$20.6M – 120
2013
Q2 		$20.6M Buy
+1,779,622
New +$14M 0.97% 43

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Deerfield Management's CYTK Position: Q4 2024 in Review

Deerfield Management sold out of Cytokinetics (CYTK) in Q4 2024, closing a stake of 12,884 shares — an estimated $680K sold.

Deerfield Management first reported a position in CYTK in Q2 2013 and held it in 13 quarters. The position peaked at $59.6M in Q1 2021. 346 funds tracked by Wall St. Rank hold CYTK as of Q4 2024.

  • Deerfield Management reported no remaining Cytokinetics position as of Q4 2024 after selling out during the quarter.
  • Deerfield Management sold 12,884 Cytokinetics shares in Q4 2024, an estimated $680K.
  • Deerfield Management first reported a position in Cytokinetics in Q2 2013 and held it in 13 quarters.
  • Deerfield Management's Cytokinetics position peaked at $59.6M in Q1 2021.
  • 346 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2024.

Based on Deerfield Management's 13F filing for Q4 2024, filed 14 Feb 2025.